WO1993003734A1 - Procede servant a abaisser les taux de lipides sanguins - Google Patents

Procede servant a abaisser les taux de lipides sanguins Download PDF

Info

Publication number
WO1993003734A1
WO1993003734A1 PCT/US1992/006828 US9206828W WO9303734A1 WO 1993003734 A1 WO1993003734 A1 WO 1993003734A1 US 9206828 W US9206828 W US 9206828W WO 9303734 A1 WO9303734 A1 WO 9303734A1
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
mimetic
pro
drug
animal
Prior art date
Application number
PCT/US1992/006828
Other languages
English (en)
Inventor
Georges H. Van Den Berghe
Harry E. Gruber
Original Assignee
Gensia, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gensia, Inc. filed Critical Gensia, Inc.
Priority to EP92918495A priority Critical patent/EP0599987A4/fr
Publication of WO1993003734A1 publication Critical patent/WO1993003734A1/fr
Priority to NO940580A priority patent/NO940580L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Abstract

Procédé servant à traiter un animal possédant un taux de lipides sériques élevé. Le procédé comprend les étapes d'identification d'un animal possédant ledit taux de lipides sérique élevé et d'introduction dans ledit animal d'une quantité lipidoréductrice d'un analogue de AMP stimulant la quinase de protéine activée par AMP.
PCT/US1992/006828 1991-08-23 1992-08-14 Procede servant a abaisser les taux de lipides sanguins WO1993003734A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP92918495A EP0599987A4 (fr) 1991-08-23 1992-08-14 Procede servant a abaisser les taux de lipides sanguins.
NO940580A NO940580L (no) 1991-08-23 1994-02-21 Fremgangsmåte for å senke blodlipidnivåer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74894491A 1991-08-23 1991-08-23
US748,944 1991-08-23
US92975292A 1992-08-12 1992-08-12
US929,752 1992-08-12

Publications (1)

Publication Number Publication Date
WO1993003734A1 true WO1993003734A1 (fr) 1993-03-04

Family

ID=27115023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/006828 WO1993003734A1 (fr) 1991-08-23 1992-08-14 Procede servant a abaisser les taux de lipides sanguins

Country Status (7)

Country Link
EP (1) EP0599987A4 (fr)
AU (1) AU2486192A (fr)
CA (1) CA2115675A1 (fr)
IL (1) IL102895A0 (fr)
MX (1) MX9204880A (fr)
NO (1) NO940580L (fr)
WO (1) WO1993003734A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037371A2 (fr) * 2001-10-31 2003-05-08 Universite Libre De Bruxelles Agonistes de kinase amp ou promedicaments d'adenosine en tant qu'agents immunostimulants
US7560435B2 (en) 2002-03-21 2009-07-14 Advanced In Vitro Cell Technologies, S. A. Therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine)
US8895520B2 (en) 2011-10-26 2014-11-25 Universite Nice Sophia Antipolis Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide
KR20160060137A (ko) * 2013-09-26 2016-05-27 에너지네시스 바이오메디컬 컴퍼니 리미티드 Ampk 활성화 화합물 및 이의 용도
WO2020050935A2 (fr) 2018-08-06 2020-03-12 Skylark Bioscience Llc Composés activant la protéine kinase activée par l'amp et leurs utilisations
US11779590B2 (en) 2020-10-30 2023-10-10 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2026040A1 (de) * 1970-05-27 1971-12-09 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Imidazolnbosylcyclophosphate
US3919192A (en) * 1972-05-22 1975-11-11 Icn Pharmaceuticals 5-Amino-4-substituted imidazole nucleotides
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US4912092A (en) * 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2026040A1 (de) * 1970-05-27 1971-12-09 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Imidazolnbosylcyclophosphate
US3919192A (en) * 1972-05-22 1975-11-11 Icn Pharmaceuticals 5-Amino-4-substituted imidazole nucleotides
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US4912092A (en) * 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Diabetes/Metabolism Reviews, Vol. 3(3), issued 1987, LOPES-VIRELLA et al., "Pharmacological Treatment of Lipid Disorders in Diabetes Mellitus", pages 691-722, entire document. *
European Heart Journal, Vol. 11(Suppl. H), issued 1990, SCHWANDT, "The Triglyceride Controversy: A Review of the Data", pages 38-43, entire document. *
European Heart Journal, Vol. 11, issued 1990, BRENNER et al., "The Intraindividual Variability of Fasting Triglyceride - A Challenge for Further Standardization", pages 1054-1058, entire document. *
Journal of Clinical Endocrinology and Metabolism, Vol. 72(4), issued 1991, LEWIS et al., "Fasting Hypertriglyceriademia in Noninsulin-Dependent Diabetes Mellitus is an Important Predictor of Postprandial Lipid and Lipoprotein Abnormalities", pages 934-944, entire document. *
Journal of Clinical Investigation, Vol. 81, issued June 1988, HAVEL, "Lowering Cholesterol", pages 1653-1600, entire document. *
See also references of EP0599987A4 *
The American Journal of Medicine, Vol. 90, issued February 1991, GRUNFELD et al., "Circulating Interferon-o Levels and Hypertriglyceridemia in the Acquired Immunodeficiency Syndrome", pages 154-162, entire document. *
The New England Journal of Medicine, Vol. 312, issued 16 May 1985, SCHAEFER et al., "Pathogenesis and Management of Lipoprotein Disorders", pages 1300-1310, entire document. *
The New England Journal of Medicine, Vol. 319, issued 07 July 1988, GRUNDY, "HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia", pages 23-33, entire document. *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037371A2 (fr) * 2001-10-31 2003-05-08 Universite Libre De Bruxelles Agonistes de kinase amp ou promedicaments d'adenosine en tant qu'agents immunostimulants
WO2003037371A3 (fr) * 2001-10-31 2004-10-28 Univ Bruxelles Agonistes de kinase amp ou promedicaments d'adenosine en tant qu'agents immunostimulants
US7560435B2 (en) 2002-03-21 2009-07-14 Advanced In Vitro Cell Technologies, S. A. Therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine)
US8895520B2 (en) 2011-10-26 2014-11-25 Universite Nice Sophia Antipolis Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide
EP3050567A4 (fr) * 2013-09-26 2017-04-05 Energenesis Biomedical Co., Ltd. Composé servant à l'activation de l'ampk et ses utilisations
EP3050567A1 (fr) * 2013-09-26 2016-08-03 Energenesis Biomedical Co., Ltd. Composé servant à l'activation de l'ampk et ses utilisations
KR20160060137A (ko) * 2013-09-26 2016-05-27 에너지네시스 바이오메디컬 컴퍼니 리미티드 Ampk 활성화 화합물 및 이의 용도
KR102101465B1 (ko) * 2013-09-26 2020-04-17 에너지네시스 바이오메디컬 컴퍼니 리미티드 Ampk 활성화 화합물 및 이의 용도
KR20200041392A (ko) * 2013-09-26 2020-04-21 에너지네시스 바이오메디컬 컴퍼니 리미티드 Ampk 활성화 화합물 및 이의 용도
EP3769766A1 (fr) * 2013-09-26 2021-01-27 Energenesis Biomedical Co., Ltd. Adenine pour activer ampk et ses utilisations médicales
KR102248806B1 (ko) * 2013-09-26 2021-05-10 에너지네시스 바이오메디컬 컴퍼니 리미티드 Ampk 활성화 화합물 및 이의 용도
WO2020050935A2 (fr) 2018-08-06 2020-03-12 Skylark Bioscience Llc Composés activant la protéine kinase activée par l'amp et leurs utilisations
US11834469B2 (en) 2018-08-06 2023-12-05 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof
US11779590B2 (en) 2020-10-30 2023-10-10 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof

Also Published As

Publication number Publication date
NO940580L (no) 1994-04-25
AU2486192A (en) 1993-03-16
EP0599987A4 (fr) 1995-02-01
IL102895A0 (en) 1993-01-31
EP0599987A1 (fr) 1994-06-08
NO940580D0 (no) 1994-02-21
MX9204880A (es) 1993-04-01
CA2115675A1 (fr) 1993-03-04

Similar Documents

Publication Publication Date Title
Steinberg et al. AMP-activated protein kinase: the current landscape for drug development
Gomez-Munoz et al. Cell-permeable ceramides inhibit the stimulation of DNA synthesis and phospholipase D activity by phosphatidate and lysophosphatidate in rat fibroblasts.
Öhrvall et al. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non—Insulin-dependent diabetes mellitus and hyperlipoproteinemia
Zhou et al. Berberine attenuates cAMP-induced lipolysis via reducing the inhibition of phosphodiesterase in 3T3-L1 adipocytes
Mulhall et al. Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy
Ferrara et al. Effects of alpha-adrenergic and beta-adrenergic receptor blockade on lipid metabolism
Dekkers et al. Distinct PKA and Epac compartmentalization in airway function and plasticity
Sajan et al. Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C–ι
US20050209243A1 (en) Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities
CN112870187A (zh) 贝壳杉烷类化合物在制备人体组织中磷酸二酯酶活性的调节剂的药物应用
Wu et al. KMUP‐1, a xanthine derivative, induces relaxation of guinea‐pig isolated trachea: the role of the epithelium, cyclic nucleotides and K+ channels
WO1993003734A1 (fr) Procede servant a abaisser les taux de lipides sanguins
Gibbons et al. Regulation of cholesterol synthesis in the liver and mammary gland of the lactating rat
CA1119956A (fr) Procede et compose pour abaisser la tension arterielle chez les animaux
Kurata et al. Structural evaluation of glucose analogues on feeding elicitation in rat
Cui et al. The role of AMPK in macrophage metabolism, function and polarisation
US6191169B1 (en) Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
Morand et al. Importance of the modulation of glycolysis in the control of lactate metabolism by fatty acids in isolated hepatocytes from fed rats
JP2017507930A (ja) ＩＫＫε／ＴＢＫ１阻害剤とベータアドレナリン作動性アゴニストまたは交感神経系活性化剤との組合せ
Mochida et al. Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor
Rossato et al. Simvastatin influences testicular steroidogenesis in human
WO2001093873A1 (fr) Utilisation de aicar et de composes associes
JPH07500093A (ja) 脂質血中レベルを減少させる方法
Katz Metabolism of lipids
JP2003238410A (ja) インスリン抵抗性解除剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2115675

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992918495

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992918495

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992918495

Country of ref document: EP